154 related articles for article (PubMed ID: 32815449)
1. Three-year results of denosumab treatment for osteoporosis in women with rheumatoid arthritis and primary osteoporosis: A clinical observational study.
Mochizuki T; Yano K; Ikari K; Hiroshima R; Nasu Y; Okazaki K
Mod Rheumatol; 2021 May; 31(3):600-606. PubMed ID: 32815449
[TBL] [Abstract][Full Text] [Related]
2. Denosumab significantly improves bone mineral density with or without bisphosphonate pre-treatment in osteoporosis with rheumatoid arthritis : Denosumab improves bone mineral density in osteoporosis with rheumatoid arthritis.
Nakamura Y; Suzuki T; Kato H
Arch Osteoporos; 2017 Sep; 12(1):80. PubMed ID: 28936606
[TBL] [Abstract][Full Text] [Related]
3. Predictors of denosumab efficacy in treating osteoporosis in patients with rheumatoid arthritis: a Japanese multicenter study.
Hattori K; Hirano Y; Kanayama Y; Takahashi N; Ishiguro N; Kojima T
Nagoya J Med Sci; 2019 Nov; 81(4):571-585. PubMed ID: 31849375
[TBL] [Abstract][Full Text] [Related]
4. Comparable efficacy of denosumab and romosozumab in patients with rheumatoid arthritis receiving glucocorticoid administration.
Kobayakawa T; Miyazaki A; Kanayama Y; Hirano Y; Takahashi J; Suzuki T; Nakamura Y
Mod Rheumatol; 2023 Jan; 33(1):96-103. PubMed ID: 35234889
[TBL] [Abstract][Full Text] [Related]
5. Vitamin D and Calcium Are Required during Denosumab Treatment in Osteoporosis with Rheumatoid Arthritis.
Nakamura Y; Suzuki T; Yoshida T; Yamazaki H; Kato H
Nutrients; 2017 Apr; 9(5):. PubMed ID: 28445420
[TBL] [Abstract][Full Text] [Related]
6. Significant improvement of bone mineral density by denosumab without bisphosphonate pre-treatment in glucocorticoid-induced osteoporosis.
Suzuki T; Nakamura Y; Kato H
Mod Rheumatol; 2018 Sep; 28(5):885-889. PubMed ID: 29251033
[TBL] [Abstract][Full Text] [Related]
7. Comparison of romosozumab versus denosumab treatment on bone mineral density after 1 year in rheumatoid arthritis patients with severe osteoporosis: A randomized clinical pilot study.
Mochizuki T; Yano K; Ikari K; Hiroshima R; Okazaki K
Mod Rheumatol; 2023 Apr; 33(3):490-495. PubMed ID: 35689558
[TBL] [Abstract][Full Text] [Related]
8. Assessment of Distal Radius Bone Mineral Density in Osteoporosis Patients Receiving Denosumab, Including Those with Rheumatoid Arthritis and Those Receiving Oral Glucocorticoids.
Matsuno H
Drugs R D; 2016 Dec; 16(4):347-353. PubMed ID: 27766589
[TBL] [Abstract][Full Text] [Related]
9. Determination of serum bone-related minerals during denosumab treatment in osteoporosis patients with rheumatoid arthritis: Mineral change by denosumab in osteoporosis with rheumatoid arthritis.
Suzuki T; Nakamura Y; Kato H
Clin Nutr ESPEN; 2018 Aug; 26():53-56. PubMed ID: 29908683
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the efficacy of denosumab and bisphosphonates for treating secondary osteoporosis in patients with rheumatoid arthritis.
Kinoshita H; Miyakoshi N; Kashiwagura T; Kasukawa Y; Sugimura Y; Shimada Y
Mod Rheumatol; 2017 Jul; 27(4):582-586. PubMed ID: 27659808
[TBL] [Abstract][Full Text] [Related]
11. The comparable efficacy of denosumab on bone mineral density in rheumatoid arthritis patients with postmenopausal osteoporosis: A retrospective case-control study.
Kim SK; Kim JW; Lee H; Park SH; Choe JY; Kim B
Medicine (Baltimore); 2023 Jun; 102(26):e34219. PubMed ID: 37390268
[TBL] [Abstract][Full Text] [Related]
12. Effects of once-monthly minodronate versus risedronate in osteoporosis patients with rheumatoid arthritis: a 12-month randomized head-to-head comparison.
Kumagai K; Harigane K; Kusayama Y; Tezuka T; Choe H; Inaba Y; Saito T
Osteoporos Int; 2018 Jul; 29(7):1637-1642. PubMed ID: 29574518
[TBL] [Abstract][Full Text] [Related]
13. Effects of bone remodeling agents following teriparatide treatment.
Burkard D; Beckett T; Kourtjian E; Messingschlager C; Sipahi R; Padley M; Stubbart J
Osteoporos Int; 2018 Jun; 29(6):1351-1357. PubMed ID: 29541794
[TBL] [Abstract][Full Text] [Related]
14. Meta-analysis of the effects of denosumab and romosozumab on bone mineral density and turnover markers in patients with osteoporosis.
Hu M; Zhang Y; Guo J; Guo C; Yang X; Ma X; Xu H; Xiang S
Front Endocrinol (Lausanne); 2023; 14():1188969. PubMed ID: 37529613
[TBL] [Abstract][Full Text] [Related]
15. Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis: Final Results of a Twenty-Four-Month Randomized, Double-Blind, Double-Dummy Trial.
Saag KG; Pannacciulli N; Geusens P; Adachi JD; Messina OD; Morales-Torres J; Emkey R; Butler PW; Yin X; Lems WF
Arthritis Rheumatol; 2019 Jul; 71(7):1174-1184. PubMed ID: 30816640
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of 4-year denosumab treatment alone or in combination with teriparatide in Japanese postmenopausal osteoporotic women.
Suzuki T; Nakamura Y; Kato H
Mod Rheumatol; 2019 Jul; 29(4):676-681. PubMed ID: 30217118
[No Abstract] [Full Text] [Related]
17. Denosumab increases sublesional bone mass in osteoporotic individuals with recent spinal cord injury.
Gifre L; Vidal J; Carrasco JL; Muxi A; Portell E; Monegal A; Guañabens N; Peris P
Osteoporos Int; 2016 Jan; 27(1):405-10. PubMed ID: 26423406
[TBL] [Abstract][Full Text] [Related]
18. Effects of denosumab treatment on bone mineral density and joint destruction in patients with rheumatoid arthritis.
Mochizuki T; Yano K; Ikari K; Kawakami K; Hiroshima R; Koenuma N; Ishibashi M; Momohara S
J Bone Miner Metab; 2018 Jul; 36(4):431-438. PubMed ID: 28681148
[TBL] [Abstract][Full Text] [Related]
19. Impact of denosumab discontinuation on changes in bone mineral density and bone erosion in rheumatoid arthritis patients.
Tanaka S; Kobayashi M; Saito K; Takita A
Mod Rheumatol; 2022 Feb; 32(2):284-291. PubMed ID: 34850085
[TBL] [Abstract][Full Text] [Related]
20. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study.
Papapoulos S; Lippuner K; Roux C; Lin CJ; Kendler DL; Lewiecki EM; Brandi ML; Czerwiński E; Franek E; Lakatos P; Mautalen C; Minisola S; Reginster JY; Jensen S; Daizadeh NS; Wang A; Gavin M; Libanati C; Wagman RB; Bone HG
Osteoporos Int; 2015 Dec; 26(12):2773-83. PubMed ID: 26202488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
